21st-23rd May 2019

Boston, USA

Register Interest 

Day One
Monday February 26th, 2018

Day Two
Tuesday February 27th, 2018

08.00
Registration & Coffee

09.00
Chairperson’s Opening Remarks

Editing without Bounds; Realizing the Limitless Potential of CRISPR

09.10
In Vivo Genome Editing with CRISPR/Cas9 Nano Formulations

Synopsis

  • Advancing nanoparticle delivery for gene-editing to specific tissues
  • What is on the horizon to enhance in vivo delivery?

09.40
Engineering T Cell Circuitry

Synopsis

  • Cas9 ribonucleoproteins (Cas9 RNPs) enable rapid and programmable non-viral knockout and knock-in genome-editing in human T cells
  • We aim to understand how sequence variation throughout the human genome affects T cell circuits in health and disease
  • Cas9 RNP technology in combination with cell-based treatments holds great potential for therapeutic genome engineering

10.10
A Rapid, Simple, High-throughput Compatible Approach to Generating CRISPR/Cas9 Knock-out Cell Lines

  • Meiye Wu Senior Scientist, Reagent R&D, Bio-Rad Inc

Synopsis

  • Streamlined CRISPR/KO method that leverages ddPCR™ and HRM™ to bypass dreaded screening pain points
  • Automation compatible approach that will enable high-throughput KO cell line generation for genome-scale functional studies

10.40
Morning Refreshments

11.10 Easi-CRISPR: an Efficient Strategy for Generation of large-size-DNA knock-in Animal Models

  • The presentation will cover latest developments in enhancing insertion of larger DNA molecules.
  • The CRISPR strategies that help rapid development of much-needed animal models.

Guru Channabasavaiah, Director, UNMC

11.40 GenCRISPRTM Technology Makes Genome Editing Easy

  • Cases studies to show versatility of GenCRISPRTM on genome editing
  • Delivery of gRNA-Cas9 efficiently with lentivirus
  • RNP facilitate genome editing in leukemia cell lines

Leon Song, Director, Genscript

11.55 Optimizing the Activities and Specificities of CRISPR-Cas9 and Cpf1 Nucleases

  • Genome editing nucleases such as CRISPR-Cas9 and Cpf1 can be engineered to impart improved properties
  • Targeting range can be expanded by evolving variants that can target previously inaccessible sites
  • Genome-wide specificity can be improved with novel engineered variants
  • Methods to define these improved properties

Ben Kleinstiver, Instructor, Harvard Medical School

12.25 An Automated Single Cell Cloning System for gene-editing: introducing the new VIPS system

  • The unique combination of single cell seeding with whole well image verification for a single cell all in one instrument
  • Positioning against the current techniques used by scientists of limiting dilutions and FACS
  • Examples of data with commercial cell lines for typical seeding and cloning efficiencies
  • Additional workflow benefits for CRISPR scientists will also be presented

Ian Taylor, Sales & Marketing Manager, Solentim

11.10 Cas-CLOVER™ Gene Editing of Autologous and Allogeneic CAR-T Therapies

  • Cas-CLOVER™ is a safe and effective gene editing technology hybrid between CRISPR/Cas9 (using gRNA targeting) and TALEN (requiring dimerization for function)
  • Enhance potency of autologous CAR-T cells within the tumor microenvironment
  •  Production of ‘universal’ allogeneic CAR-T cells

Devon Shedlock, Vice President, Preclinical Development, Poseida

11.40 Cibus’ Trait Machine is Accelerating Plan Breeding Using the Rapid Trait Development System (RTDS™) to Benefit Consumers, Farmers and Processors

  • Over thousands of years, breeders have relied on random variation for crop improvement
  • Cibus has developed a process called the Rapid Trait Development System (RTDS) that combines advanced cell culture and a range of modern mutagenesis tools to accelerate plant breeding by precisely specifying beneficial typographical changes in crop genomes much like a word processor on your computer
  • What used to be a random process taking many years can now be accomplished in months with outcomes indistinguishable from those that can occur in nature

Greg Gocal, EVP & CSO, Cibus

11.55 Translational and Basic Research-Based CRISPR Cas9 Genome Editing of Human Hematopoietic Stem Cells

  • Summarizing the current state-of-the-art CRISPR strategies to translate genome editing to the clinic for treatment of monogenic blood and immune system disorders
  • Summarizing preclinical IND-enabling studies for correcting the Glu6Val mutation in autologous HSPCs
  • Summarizing advanced CRISPR biotechnologies to interrogate HSPC gene functions

Danny Dever, Instructor, Stanford

12.25 CRISPR Genetic Screens: An Effective Tool to Identify Genes Responsible for Disease Pathologies and Drug Efficacy

  • Complex pools of lentiviral-based sgRNA libraries provide one of the most effective tools to uncover the functional genetic elements that regulate disease pathologies, drug efficacy, and other biological responses.
  • Modifications of the standard sgRNA structure improve  effectiveness and CRISPR library performance.
  • Results of CRISPR-based gene inhibition and activation (CRISPRi and CRISPRa) screens differ considerably depending on the sgRNA design of the libraries

Paul Diehl, COO, Cellecta

13.50 Understanding and Manipulating the Kinetics of Cas9 Activity to Enhance Genome Editing

  • How to prospectively avoid “dud” sgRNAs for indel mutagenesis
  • Identifying the rate limiting step during Cas9-editing in cells
  • Manipulating Cas9 to provide multi-turnover nuclease activity

Brad Merill, Associate Professor, University of Illinois at Chicago

14.20 CRISPR-Cas9 Mediated Transcriptional Activation using Synthetic crRNA

  • A guide RNA platform enabling robust overexpression of genes in their endogenous context
  • CRISPR-Cas9 gene knockout and activation in onegene- per well format allows for study of biological mechanisms in complex assay

James Goldmeyer, Product Manager, Dharmacon

14.50 CRISPR Functional Screening for Human Primary Cells

  • Pooled screens using a quantitative cellular marker in human primary cells provide an effective approach for target discovery
  • Quick follow up with pharmacologic inhibition can help accelerate target validation and prioritization.
  • Combining FACS-Based CRISPR screen and human genetic datasets might provide novel, valuable and actionable insights.

Chen-Lin Hsieh, Senior Scientist, Abbvie

13.50 Future Safety and Efficacy: Exploring the Alignment of CRISPR and the Future of Therapeutic Development to the Future of Clinical Trial Design

  • Discuss how drug development and regulatory processes need to continue to embrace data science technology to enhance clinical trial efficiency for therapeutics using CRISPR as well as other innovations
  • Explore the history of the Virtual Subject model for Clinical Trial development and execution
  • Address opportunities, considerations, and best practices to drive toward the frontier of executing trials with Virtual Subjects

Dan Tierno, Strategic Implementation Manager, Bayer

14.20 Taking CRISPR to the Clinic

  • Efficient editing at clinical scale and in long-term repopulating HSCs
  • Editing results in relevant pharmocodynamic effect
  • Careful choice of gRNAs results in high specificity and no detectible off-target events
  • Progressing to the clinic after scale-up and regulatory/toxicology studies

TJ Cradick, Head of Genome Editing, CRISPR Therapeutics

14.50 Application of CRISPR Method to Interpret GWAS in COPD

  • Connecting non-coding variants in GWAS loci with disease susceptible genes in COPD
  • Phenotypic recapitulation of human COPD in murine genetic models
  • Application of CRISPR/Cas-9 targeting COPD GWAS locus

Anny Xiaobo Zhou, Assistant Professor, Harvard

12.50
Networking Lunch

15.20
Afternoon Refreshments

15.50
How do you know? Measurements and Standards to Support Confidence in Genome Editing

Synopsis

  • NIST is the measurement institute of the U.S., supplying unbiased expertise in measurements and standards to support growth in all sectors of economy and commerce including healthcare and the bio-economy
  • NIST has been working with experts in the genome editing field to identify precompetitive needs for establishing confidence in assessing the results of genome editing protocols
  • NIST is launching a NIST led Genome Editing Consortium as a public private partnership to bring together academia, non-profit, industry and other government to generate best practices, high quality data, a standard lexicon and data/metadata norms for the genome editing field

16.20
Genome Editing with ZFN, Targetron, and CRISPR-Cas Systems

Synopsis

  • Overview of in-house genome editing innovations at MilliporeSigma
  • Surmounting limitations on CRISPR imposed by chromatin
  • Different RNA-guided options for bacterial genome editing
  • CRISPR screening tools including nuclease and transcriptional modes.

16.50
Synthetic sgRNA Enables Highly Efficient & Consistent CRISPR Editing of Cells for Automation, Cell Engineering and Therapeutic Applications

Synopsis

  • Achieving consistent and high editing efficiencies with CRISPR is critical for automation, cell engineering and therapeutic applications with primary cells, and remains a significant challenge.
  • Through a collaborative effort, we demonstrate that use of synthetic sgRNA for CRISPR yields improved and consistent editing efficiencies that are required for such applications.

 

17.20
Genome-Scale Pooled CRISPR Screening For Drug Targets Anchored in Alzheimer’s Disease Genetics

Synopsis

  • Human genetic studies are being used to estimate the potential safety and efficacy of drug targets prior to pharmaceutical investment
  • Genes and pathways identified through genetic association studies are often challenging to therapeutically modulate
  • We are applying genome-scale pooled CRISPR screening to identify “druggable” regulators of Alzheimer’s disease genetic targets

 

 

 

18.00
Evening Drinks Reception & Table Top Discussions

Synopsis

Drive your own learning and brain storm ideas. The CRISPR speaker faculty is second to none but there is just as much knowledge in the audience as there is onstage. We want to make sure you can tap into this wealth of experience and expertise. Discover multiple perspectives on the key issues affecting the CRISPR field by joining roundtable discussions, specifically designed so you can learn from your fellow gene-editing peers.

round tables day 1